The importance of RANKL in promoting tumor growth in bone and osteolysis induced by metastatic breast cancer cells is also well established [38] and has led to the use of RANKL blockade to prevent fracture in patients with breast and prostate cancer [39]. The gene discussed is TNFSF11; the disease is prostate cancer.